Inhalation Preparation

Group real-time dynamics and cutting-edge information in the field of One Health 

Your location:
Inhalation Preparation

In 2019, the first new Category 4 registered and approved respiratory preparation was launched



On April 15, 2019, Shutanlin® (Compound ipratropium bromide solution for inhalation) received the Drug Registration Approval issued by the State Food and Drug Administration. This product:

- It is the first new Category 4 registered and approved atomized solution for inhalation which is considered to have passed the consistent evaluation in China;

- As a compound preparation, it has the characteristics of synergistic effect and safe treatment;

- It is a special dosage form for aerosol treatment suitable for a wide range of people, and can reduce the risk of liquid dispensing and provide more convenient and worry-free medication options for clinic use.

[Indications]: It is suitable for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm associated with airway obstructive disease

[Administration and Dosage]: 3-4 times a day, one small vial at a time.

[Specification]: 2.5ml/vial, 10 vials/box

Service Hotline


Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved.  Powered Zhuhai